IL-3-zetakine联合CD33共刺激受体作为双CAR策略用于更安全、选择性靶向急性髓系白血病
急性髓系白血病(AML)仍存在未满足的临床需求。CD123和CD33是两种最广泛过表达的白血病干细胞标志物,但与内皮及造血干祖细胞共享表达会增加脱靶毒性风险。研究建立平衡双CAR策略,细胞因子诱导杀伤(CIK)细胞共表达第一代低亲和力抗CD123的IL-3-zetakine(IL-3z)和无激活信号域的抗CD33共刺激受体(CD33.CCR),对AML靶细胞显示强效抗肿瘤活性,对造血干祖细胞和内皮细胞无相关毒性。
要点
- CD123和CD33在白血病干细胞过表达,但与内皮及造血干祖细胞共享表达,增加脱靶毒性风险。
- CIK细胞共表达低亲和力IL-3z和CD33.CCR的双CAR策略,对AML靶细胞显示强效抗肿瘤活性。
- 该双CAR策略对造血干祖细胞和内皮细胞未显示相关毒性。
核心结论
- 优化的双CAR细胞因子诱导杀伤细胞策略可能提供机会,释放特异性靶向CD123+/CD33+白血病细胞的潜力,同时最小化对健康细胞的毒性。
研究设计与样本
- 研究建立平衡双CAR策略,使用细胞因子诱导杀伤(CIK)细胞共表达第一代低亲和力抗CD123的IL-3-zetakine(IL-3z)和无激活信号域的抗CD33共刺激受体(CD33.CCR)。
主要发现
- 共表达IL-3z和CD33.CCR的CIK细胞对AML靶细胞显示强效抗肿瘤活性。
- 该双CAR CIK细胞对造血干祖细胞和内皮细胞未显示相关毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells demonstrated a high therapeutic potential, but further development is required to ensure a safe and durable disease remission in AML, especially in elderly patients. To date, translation of CAR T-cell therapy in AML is limited by the absence of an ideal tumor-specific antigen. CD123 and CD33 are the 2 most widely overexpressed leukemic stem cell biomarkers but their shared expression with endothelial and hematopoietic stem and progenitor cells increases the risk of undesired vascular and hematologic toxicities. To counteract this issue, we established a balanced dual-CAR strategy aimed at reducing off-target toxicities while retaining full functionality against AML. Cytokine-induced killer (CIK) cells, coexpressing a first-generation low affinity anti-CD123 interleukin-3-zetakine (IL-3z) and an anti-CD33 as costimulatory receptor without activation signaling domains (CD33.CCR), demonstrated a powerful antitumor efficacy against AML targets without any relevant toxicity on hematopoietic stem and progenitor cells and endothelial cells. The proposed optimized dual-CAR cytokine-induced killer cell strategy could offer the opportunity to unleash the potential of specifically targeting CD123+/CD33+ leukemic cells while minimizing toxicity against healthy cells.
引用
- Perriello VM, Rotiroti MC, Pisani I, et al. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. Blood Adv. 2023. PMID: 36521101. doi:10.1182/bloodadvances.2022008762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。